

1 **Cell-density independent increased lymphocyte production and loss rates post-autologous**
2 **hematopoietic stem cell transplantation**

3 Mariona Baliu-Piqué^{1*}, Vera van Hoven^{2*}, Julia Drylewicz^{1*}, Lotte E. van der Wagen³, Anke Janssen¹,
4 Sigrid A. Otto¹, Menno C. van Zelm⁴, Rob J. de Boer⁵, Jürgen Kuball^{1,3}, José A.M. Borghans^{1*} and Kiki
5 Tesselaar^{1*}

6 ¹Center for Translational Immunology, University Medical Center Utrecht, The Netherlands;

7 ²Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, The Netherlands;

8 ³Department of Hematology, University Medical Center Utrecht, The Netherlands;

9 ⁴Department of Immunology and Pathology, Monash University and Alfred Hospital, Melbourne;

10 ⁵Theoretical Biology, Utrecht University, Utrecht, The Netherlands

11 *These authors contributed equally to this work

12 **Corresponding author:**

13 Kiki Tesselaar, PhD

14 Center for Translational Immunology

15 University Medical Center Utrecht (UMCU)

16 P.O. Box 85090, 3508 AB Utrecht, The Netherlands

17 T: +31 (0)88755394; E-mail: K.Tesselaar@umcutrecht.nl

18 **Abstract**

19 Lymphocyte numbers need to be quite tightly regulated. It is generally assumed that
20 lymphocyte production and survival rates increase homeostatically when lymphocyte numbers
21 decrease. This widely-accepted concept is largely based on experiments in mice. In humans,
22 lymphocyte reconstitution usually occurs very slowly, which challenges the idea that density
23 dependent homeostasis aids recovery from lymphopenia. Using *in vivo* deuterium labelling, we
24 quantified lymphocyte production and survival rates in patients who underwent an autologous
25 hematopoietic stem cell transplantation (autoHSCT). We indeed found that the production rates of
26 most T-cell and B-cell subsets in autoHSCT-patients were 2 to 8-times higher than in healthy controls.
27 These increased lymphocyte production rates went hand in hand with a 3 to 9-fold increase in cell loss
28 rates, and both rates did not normalize when cell numbers did. This challenges the concept of
29 homeostatic regulation of lymphocyte production and survival rates in humans.

30 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

31 Introduction

32 Under healthy conditions, the peripheral T- and B-cell populations are maintained at relatively
33 stable numbers throughout life ^{1,2}. Homeostatic mechanisms are thought to regulate lymphocyte
34 production and survival rates in a density-dependent manner. Indeed, studies in rodents have shown
35 that lymphocyte division and survival rates increase in response to severe lymphopenic conditions ³.
36 Robust peripheral proliferation of T-cells occurs both upon adoptive cell transfer into severely
37 lymphocyte-depleted mice, and in partially immune-depleted hosts in the absence of adoptive cell
38 transfer, a phenomenon termed lymphopenia-induced proliferation (LIP) ³⁻⁶. Similarly, rapid
39 proliferation and extended survival of B-cells occur after adoptive cell transfer into B-cell deficient
40 hosts and correlate with peripheral B-cell numbers ⁷.

41 In analogy, it is generally assumed that lymphopenic conditions induce alterations in lymphocyte
42 dynamics in humans. However, in humans full recovery of the T-cell compartment following an
43 autologous hematopoietic stem cell (autoHSCT) is notoriously slow, often taking several years ⁸⁻¹¹.
44 On the basis of elevated frequencies of Ki-67⁺ cells, severe lymphopenia arising after HSCT and
45 lymphocyte-depleting treatments has been associated with increased proliferation of naive and
46 memory T-cells ¹²⁻¹⁵. However, elevated frequencies of Ki-67⁺ cells were shown to decline within 3 to
47 6 months after cell depletion, despite the fact that patients were still deeply lymphopenic ¹³⁻¹⁵.
48 Furthermore, increased T-cell proliferation rates after allogeneic HSCT have been shown to correlate
49 with the occurrence of graft-versus-host disease (GVHD) and infectious-disease-related
50 complications ¹⁴. Together, these observations question whether homeostatic mechanisms are
51 induced to compensate for low lymphocyte numbers in humans undergoing HSCT. It remains unclear
52 to what extent increased T-cell proliferation post-HSCT reflects a T-cell density-dependent response to
53 lymphopenia, or an immune response triggered by therapy-related tissue damage, infectious
54 complications, or immune activation.

55 To elucidate whether lymphocyte production and death rates in humans are regulated in a
56 density-dependent manner, we used *in vivo* deuterium labelling to quantify the production and loss
57 rates of different T- and B-cell subsets in patients who received an autologous HSCT (autoHSCT), and
58 had no signs of clinically manifested infections or GVHD. Twelve months after autoHSCT, absolute
59 numbers of CD4⁺ T-cells and memory and natural effector B-cells in these patients were still lower than
60 in healthy individuals, while CD8⁺ T-cell and naive B-cell numbers had already recovered to healthy
61 control values. Deuterium labelling revealed that the production rates of most lymphocyte subsets,
62 even those that had already reconstituted, were significantly higher in patients post-autoHSCT than in
63 healthy individuals. These increased rates of T- and B-cell production could only be reconciled with the

64 observed slow changes in lymphocyte numbers over time if lymphocyte loss rates were also
65 significantly increased, impeding a timely reconstitution of the lymphocyte pool post-autoHSCT.

66 **Materials and Methods**

67 Complete Materials and Methods can be found as Supplementary Information.

68 **Patient characteristics**

69 Six patients who received an autoHSCT for the treatment of a hematologic malignancy were
70 enrolled in the study after having provided written informed consent. Following repeated
71 subcutaneous injections with granulocyte-colony stimulating factor (G-CSF), stem cells were obtained
72 by leukapheresis of peripheral blood. Patients received a non T-cell depleted graft; the average number
73 of CD34⁺ cells transplanted was 5.03x10⁶ cells/kg (median, 4.12; range, 1.82-12.38). Patients were
74 included in the study between 196 and 420 days after autoHSCT, and had no signs of transplantation-
75 related complications, severe infections (HIV, HBV, HCV), other liver disease, active uncontrolled
76 infections (such as infectious mononucleosis), inadequate liver or kidney function, or cardiovascular
77 disease before and during the study. Additional inclusion criteria were: fully transfusion-independent
78 at start of the study, hemoglobin level ≥ 6 mmol/l, and platelet count $\geq 50 \times 10^9$ /L. Any use of medication
79 during the study was unrelated to the malignancy and the HSCT (Figure 1). In order to compare the
80 phenotypes of the B- and T-cell compartments of patients to those of age-matched healthy individuals,
81 we used data from healthy individuals from a previous study ¹⁶, and additional blood samples were
82 collected from healthy volunteers not following the labelling protocol after having provided informed
83 consent. This study was approved by the medical ethical committee of the University Medical Center
84 Utrecht and conducted in accordance with the Helsinki Declaration.

85 ***In vivo* deuterium labelling**

86 *In vivo* deuterium labelling was performed as previously described with small adaptations ¹⁶.
87 Briefly, patients received an oral ramp-up dose of 7.5 ml of heavy water (²H₂O, 99.8% enriched,
88 Cambridge Isotope Laboratories) per kg body water on the first day of the study, and drank a daily
89 maintenance dose of 1.25 ml ²H₂O per kg body water for 6 weeks. To reduce the study burden, the
90 labelling period of patients was 3 weeks shorter than the previously used labelling period for healthy
91 individuals.

92 **Cell isolation, flow cytometry and cell sorting**

93 Peripheral blood mononuclear cells were obtained by Ficoll-Paque (GE Healthcare, Little
94 Chalfont, UK) density gradient centrifugation from heparinized blood. Granulocytes were obtained by
95 2 cycles of erythrocyte lysis (155mM NH₄Cl, 10mM KHCO₃, 0.1mM Na₂-EDTA, pH=7.0) of the

96 granulocyte/erythrocyte layer. To determine baseline enrichment, total peripheral blood mononuclear
97 cells were frozen on the first day of the study, prior to $^2\text{H}_2\text{O}$ intake.

98 Absolute cell numbers were determined using TruCount tubes (BD Biosciences, San Jose, CA,
99 USA), and cell cycle analysis was performed by measuring expression of Ki-67. Samples were analysed
100 on an LSR-II or LSR-Fortessa flow cytometer using FACS Diva software (BD Biosciences).

101 $\text{CD}19^+$ naive ($\text{IgM}^+\text{CD}27^-$), Ig class-switched ($\text{IgM}^-\text{CD}27^+$) and IgM^+ ($\text{IgM}^+\text{CD}27^+$) memory B-cells
102 and $\text{CD}3^+\text{CD}4^+$ and $\text{CD}3^+\text{CD}8^+$ naive ($\text{CD}27^+\text{CD}45\text{RO}^-$) and memory ($\text{CD}45\text{RO}^+$) T-cells were sorted on a
103 FACS Aria II or FACS Aria III cell sorter using FACS Diva software (BD Biosciences). Flow cytometric
104 analyses and cell sorting were always performed on freshly isolated material. Representative density
105 dot plots and the gating strategy for TruCount analysis and cell sorting are shown in Sup. Figure 1.

106 **Statistical analyses**

107 Medians were compared between groups using Mann–Whitney tests. Correlations were
108 analysed using the Spearman’s rank test (GraphPad Software, Inc). Differences with a p -value <0.05
109 were considered significant.

110 **Results**

111 **Heterogeneous T-cell reconstitution kinetics post-autoHSCT**

112 To investigate whether lymphocyte production and loss depend on cell numbers during
113 lymphopenia in humans, we quantified the production and loss rates of B- and T-cells in 6 patients who
114 received an autoHSCT for the treatment of haematological malignancies. Patients were included in the
115 study between 196 days and 420 days post-autoHSCT, they received deuterated water ($^2\text{H}_2\text{O}$) for six
116 weeks, and were followed for approximately one year after start of the labelling period (Figure 1).
117 *Patient B* withdrew from the study 10 weeks after the start of $^2\text{H}_2\text{O}$ labelling due to infectious
118 complications unrelated to participation in the study. All other patients had no complications that
119 needed treatment during the study follow-up, which was supported by CRP levels in the normal range
120 (Sup. Figure 2).

121 The sub-optimal T-cell recovery observed in the peripheral blood of patients post auto-HSCT
122 (Figure 2A) was largely due to the slow reconstitution of $\text{CD}4^+$ T-cells (Figure 2B). At the start of $^2\text{H}_2\text{O}$
123 labelling, $\text{CD}8^+$ T-cell numbers had reached normal levels in most patients, whereas $\text{CD}4^+$ T-cell
124 numbers remained below normal levels even 1.5 years post-autoHSCT. This resulted in an inverse
125 $\text{CD}4:\text{CD}8$ ratio in all patients except for *patient C* (Figure 2C), who experienced extremely slow $\text{CD}8^+$ T-
126 cell reconstitution (Figure 2D). Naive ($\text{CD}45\text{RO}^-\text{CD}27^+$) $\text{CD}4^+$ T-cell numbers remained below normal
127 levels throughout the 2-year follow-up period, whereas memory ($\text{CD}45\text{RO}^+$) $\text{CD}4^+$ T-cells reached the

128 lower range of normal levels around 400 days post-autoHSCT (Figure 2B). Naive and memory CD8⁺ T-
129 cell numbers were at normal or supra-normal levels at the start of the study in all patients except for
130 *patient C* (Figure 2D). In line with cell numbers, for most patients the fractions of naive cells, central
131 memory (CM, CD45RO⁺CD27⁺), effector memory (EM, CD45RO⁺CD27⁻) and effector (CD45RO⁻CD27⁻) T-
132 cells differed from those in healthy controls and varied slightly over time (Figure 2E and Sup. Figure 3).

133 Because it is generally assumed that during lymphopenia the availability of growth and survival
134 factors increases, which has in particular been shown for IL-7 plasma levels^{18–22}, we also determined
135 plasma levels of IL-7 and IL-15 between 12 and 24 months post-autoHSCT. Despite the CD4⁺ T-cell
136 lymphopenia observed in these patients, their plasma concentrations of IL-7 and IL-15 and several
137 other cytokines were in the range of those of healthy controls (Sup. Figure 2).

138 **Increased CD4⁺ and CD8⁺ T-cell production rates post-autoHSCT**

139 To investigate whether low CD4⁺ T-cell numbers were associated with increased T-cell
140 production rates, we compared the level of deuterium enrichment in the DNA of the different T-cell
141 subsets between patients and controls. Deuterium enrichment analysis showed a relatively high level
142 of label incorporation in patients, despite the fact that the labelling period was 3 weeks shorter for
143 patients than for controls (Figure 3A). Using mathematical modelling we estimated the production
144 rates of the different T-cell subsets (i.e. the number of new cells produced per day, coming from a
145 source or peripheral cell division, divided by the number of resident cells in the population). We found
146 that the production rates of naive and memory CD4⁺ T-cells were, respectively, 6-times and 3-times
147 higher in patients than in controls. For naive and memory CD8⁺ T-cells, the estimated production rates
148 were approximately 8- and 4-times higher in patients compared to controls (Figure 3B, Sup. Table 1),
149 despite the fact that absolute CD8⁺ T-cell numbers had already recovered to healthy levels 12 months
150 post-transplantation.

151 **Increased proliferation of naive but not memory CD4⁺ and CD8⁺ T cells**

152 T-cell production rates as measured by deuterium labelling may reflect cell division of the subset
153 of interest or an influx of cells from a source (e.g. by thymic output) or from another subset (e.g.
154 through lymphocyte differentiation). To distinguish between these options, we first measured Ki-67
155 expression, a marker for peripheral cell division, of all lymphocyte subsets. The fraction of Ki-67⁺ cells
156 within the naive CD4⁺ and CD8⁺ T-cell pools was significantly higher in patients compared to controls
157 (Figure 4A). For the memory T-cell subsets, in contrast, the fraction of Ki-67⁺ cells of patients did not
158 differ significantly from those of controls (Figure 4A). This suggests that the increased production rates
159 of memory CD4⁺ and CD8⁺ T-cells may occur due to an increased influx from naive T-cells into the
160 memory compartment, rather than increased T-cell division within the memory T-cell pools.

161 Besides increased cell division in the naive T-cell pool, increased naive T-cell production rates
162 post-autoH SCT could in theory also be due to increased thymic output. T-cell receptor excision
163 circles (TRECs) are commonly measured to estimate thymopoiesis. Because the average TREC
164 content per T-cell declines with age²³⁻²⁵, we measured TREC contents of naive T-cells from patients,
165 cord blood, and young (on average 23 years of age) and aged (on average 68 years of age) healthy
166 individuals¹⁶. The average TREC content of naive CD4⁺ T-cells in patients was approximately 10-fold
167 higher than in aged controls, and not significantly different from that of young individuals and cord
168 blood (Figure 4B), even though all but one of the patients were more than 50 years of age. For naive
169 CD8⁺ T-cells, the average TREC content in patients was in the range of young and aged controls (Figure
170 4B). We also measured CD31 expression on naive CD4⁺ T-cells, as CD31⁺CD4⁺ T cells are known to be
171 enriched in recent thymic emigrants (RTEs)^{26,27}. The fraction of CD31⁺ cells within the naive CD4⁺ T-
172 cell population was slightly higher in patients than in aged controls and slightly lower than in young
173 controls and cord blood (Figure 4C, Sup. Figure 4). For naive T-cells, the combined Ki-67, TREC and
174 CD31 data suggest that the increased T-cell production is due to increased T-cell division, and that the
175 increased average TREC contents and percentages of CD31⁺ cells may be a direct consequence of
176 normal thymic output entering a smaller T-cell pool²⁸.

177 **Heterogeneous B-cell reconstitution kinetics post-autoH SCT**

178 Next, we studied the changes in B-cell dynamics following autoH SCT. Although total CD19⁺ B-
179 cell numbers and naive (IgM⁺CD27⁻) B-cell numbers had already reached normal or even supra-normal
180 levels by day 200 post-autoH SCT, Ig class-switched (IgM⁻CD27⁺) and IgM⁺ (IgM⁺CD27⁺) memory B-cell
181 numbers in most patients were still below, or in the lower range of, those of healthy controls
182 throughout the study period (Figure 5A, 5B and Sup. Figure 5).

183 **Increased production rates of B-cells post-autoH SCT**

184 We analysed the deuterium enrichment of the different B-cell subsets to study whether B-cell
185 production rates were increased for subsets which were still low in cell numbers (Figure 6A). The
186 production rates of Ig switched-memory B-cells and IgM⁺ memory B-cells were 3.5-times and 5-times
187 higher than in controls, respectively (Figure 6B, Sup. Table 1). Also the production rate of naive B-cells,
188 a population that had already reconstituted to supra-normal levels, remained significantly higher than
189 in healthy controls (Figure 6B, Sup. Table 1).

190 Because B-cell production may depend on peripheral B-cell division and on *de novo* bone
191 marrow output, we measured Ki-67 expression and kappa-deleting recombination excision circles
192 (KRECs), in an attempt to estimate bone marrow output. The percentages of dividing, i.e. Ki-67⁺, cells
193 within IgM⁺ and Ig switched-memory B-cells were significantly higher in patients than in healthy

194 individuals (Figure 6C). In contrast, the fraction of Ki-67⁺ cells within the naive B-cell subset was similar
195 between patients and controls (Figure 6C). Although naive B-cell peripheral division rates were not
196 increased post-autoHSCT, their production rates were 2-times higher than in controls. The replication
197 history (measured as number of cell divisions) of the naive B-cell subsets in patients tended to be lower
198 than in controls (although not significantly), suggesting that the output of naive B-cells from the bone
199 marrow rather than their peripheral proliferation rate was increased after autoHSCT (Figure 6D).

200 **Increased lymphocyte production rates are counteracted by increased lymphocyte loss rates**

201 The increased lymphocyte production rates that we observed in patients after autoHSCT may at
202 first sight suggest that, also in humans, lymphocyte production is regulated in a density-dependent
203 manner. The observation that lymphocyte production rates were also elevated for subsets for which
204 cell numbers had already normalized, however, challenges this interpretation. Another observation
205 challenging this interpretation is that for most subsets, lymphocyte numbers increased very little over
206 time, despite the significant increase in lymphocyte production. This suggests that lymphocyte loss
207 rates were also significantly increased after autoHSCT.

208 To estimate the average loss rates of all lymphocyte subsets (i.e. the number of cells lost per
209 day, by cell death, migration or differentiation, divided by the number of resident cells in the
210 population), we used the average lymphocyte production rates estimated from the deuterium labelling
211 experiments and an exponential function to describe the changes in cell numbers of each lymphocyte
212 subset over time (see Sup. material and methods). For most T-cell and B-cell subsets the average loss
213 rate was approximately 3 to 5-times higher post-autoHSCT than in healthy individuals (Figure 7, Sup.
214 Table 2). For naive CD8⁺ T-cells the average loss rate was even 9.5-times higher in patients than in
215 healthy individuals (Figure 7, Sup. Table 2). Thus, despite the fact that production rates are clearly
216 increased in patients post-autoHSCT, this increased production goes hand in hand with increased
217 lymphocyte loss rates, thereby challenging the view that it reflects a homeostatic response to low
218 lymphocyte numbers.

219 **Discussion**

220 From a homeostatic viewpoint, a response to low lymphocyte numbers could take the form of
221 increased lymphocyte production or decreased lymphocyte loss. Based on the observation that severe
222 lymphopenia in mice is associated with increased peripheral proliferation^{3-5,20}, it is widely believed
223 that lymphocyte production rates are increased when cell numbers are low. We have previously shown
224 that naive T-cell turnover rates do not increase to compensate for the at least 10-fold decline in thymic
225 output in elderly individuals¹⁶. This could be due to the relatively small degree of naive T-cell loss

226 observed during healthy ageing. Under more severe conditions of lymphopenia in humans, high
227 frequencies of proliferating lymphocytes have been observed, but these have been linked to immune
228 activation and clinical events, e.g. GVHD and opportunistic infections¹⁴. Thus, there is no convincing
229 evidence that homeostatic regulation of lymphocyte production and loss occurs in humans.

230 Our deuterium labelling study shows that in patients receiving an autoHSCT, in the absence of
231 GVHD, clinically manifested infections and transplantation-related complications, the production rates
232 of most T- and B-cell subsets were significantly increased 12 months after transplantation. Increased
233 lymphocyte production following lymphodepletion has generally been interpreted as evidence for a
234 density-dependent response to low lymphocyte numbers^{12,13,15,29,30}. Our study challenges this view for
235 two reasons: i) T- and B-cell production rates did not normalize when cell numbers did, and ii)
236 lymphocyte loss rates were also increased post-autoHSCT. This suggests that the increase in
237 lymphocyte production rates in autoHSCT patients was not simply a homeostatic response to low cell-
238 numbers. Other determinants, such as repertoire diversity or the clonality of the T-cell pool might also
239 play a role. In addition, despite the fact that the patients in our study were included up to 12 months
240 post-transplantation and were selected on the basis of being in good health, we cannot exclude that
241 the increased rates of lymphocyte production and loss in these patients reflect HSCT-related
242 complications, such as the impact of initial chemo-therapy and conditioning-therapy or sub-clinical
243 infections and inflammation, which may have gone unnoticed.

244 The observation that lymphocyte loss rates were increased post-autoHSCT is remarkable in the
245 light of the widely held view that homeostatic mechanisms could take the form of increased
246 lymphocyte survival. This concept is supported by the observation that the availability of pro-survival
247 and anti-apoptotic factors, such as IL-7³¹, increases during lymphopenia. We found that lymphocyte
248 loss rates were up to 10-fold increased after autoHSCT. This is in line with previous human studies on
249 T-cell survival after allogenic HSCT, which consistently reported that the fraction of pro-apoptotic cells
250 increases following transplantation^{15,32-34}. Although this suggests that intervention with lymphocyte
251 survival after HSCT may aid lymphocyte reconstitution, in our study, different factors may have
252 contributed to the loss of cells from the peripheral blood. Cells may have been lost from the circulation
253 by cell death, but also by lymphocyte differentiation and/or migration to the tissues. Further studies
254 need to clarify whether lymphocyte reconstitution occurs at similar rates in blood and tissues, or
255 whether lymphocyte recruitment to the tissues may be a key factor influencing the loss of lymphocytes
256 from the blood following autoHSCT.

257 Consistent with previous reports^{10,15,35}, we found that 12 months post-autoHSCT, CD4⁺ T-cell
258 numbers were below the normal range while CD8⁺ T-cells recovered more rapidly. Deuterium labelling
259 in patients revealed that the average production rates of most T-cell subsets were significantly
260 increased following autoHSCT. This increase was especially evident for naive T-cells. The high

261 percentage of Ki-67⁺ naive T-cells post-autoHSCT suggests that increased naive T-cell production is to
262 a large extent explained by increased peripheral T-cell proliferation. Memory T-cell production rates
263 (based on deuterium enrichment) were also higher in patients compared to controls, while Ki-67
264 expression suggested that memory CD4⁺ and CD8⁺ T-cell proliferation rates were not increased after
265 autoHSCT. This seeming contradiction may be explained by the fact that Ki-67, a snapshot marker, may
266 be less sensitive to detect differences in T-cell proliferation than long-term *in vivo* deuterium labelling.
267 Alternatively, the increased production rate of memory T cells post-autoHSCT may be due to increased
268 transition of naive T cells into the memory T-cell population. In mice it has been demonstrated that
269 naive T-cells adoptively transferred into immunodeficient animals can undergo division without
270 cognate antigen stimulation, thereby acquiring a memory phenotype^{36,37}.

271 If a significant part of cell production in a certain lymphocyte subset (e.g. the memory subset) is
272 indeed due to an influx from another lymphocyte subset (e.g. the naive subset), the increased
273 production rates that we observed may either reflect a true increase in cell production, or a normal
274 influx of cells entering a smaller lymphocyte population. To distinguish between these options, for
275 each lymphocyte subset and each individual, we also calculated the total number of cells produced per
276 day (i.e. coming from a source and/or from peripheral cell division), by multiplying the average
277 production rate of each lymphocyte subset with the median cell number of that subset, and compared
278 these values to those in healthy controls (data not shown). We found that total daily lymphocyte
279 production was as high as in healthy controls for naive CD4⁺ T cells and higher than in healthy controls
280 for all other lymphocyte subsets, suggesting that the increased lymphocyte production rates post-
281 autoHSCT truly reflected increased T-cell proliferation and/or an increased influx from another
282 lymphocyte compartment.

283 Measuring thymopoiesis and the contribution of recent thymic emigrants to the naive T-cell
284 pool after HSCT is not straightforward. Although increased TREC contents at first sight seem
285 suggestive for increased thymic output, T-cells bearing TRECs may in fact be overrepresented in the
286 peripheral T-cell pool post-transplantation when cell numbers are low²⁸. Hence, for naive CD4⁺ T cells,
287 whose numbers had not yet normalized, increased average TREC contents may incorrectly be
288 interpreted as evidence for increased thymic output. The finding that the average TREC content of
289 naive CD4⁺ T-cells following autoHSCT was higher than in age-matched controls provides no evidence
290 that thymic output following transplantation was higher than in healthy controls, but does imply that
291 the thymus had become functional again within 12 months after intense conditioning for autoHSCT.
292 The fact that the average TREC content of naive CD4⁺ T-cells, but not that of naive CD8⁺ T-cells, was
293 higher in patients than in healthy individuals may reflect differences in the degree of depletion of naive
294 CD4⁺ and CD8⁺ T-cells. Alternatively, it might reflect differences in the way CD4⁺ and CD8⁺ T-cells are
295 generated. In support of the latter explanation, repertoire analyses in patients receiving an autoHSCT

296 for the treatment of autoimmune diseases have suggested that CD4⁺ T-cells largely arise *de novo*, since
297 most CD4⁺ T-cell clones post-autoHSCT were not present at baseline, while CD8⁺ T-cells mainly expand
298 from cells that were already circulating pre-transplantation³⁸⁻⁴⁰.

299 To study in a population other than T-cells whether lymphocyte production and loss rates in
300 humans are regulated in a density-dependent manner, we quantified the production and loss rates of
301 different B-cell subsets. In line with previous reports⁴¹⁻⁴³, we found that 12 months after
302 transplantation, naive B-cell numbers had reconstituted to healthy (or even higher than healthy)
303 control values, while Ig class-switched and IgM⁺ memory B-cells had not yet fully recovered. The
304 delayed reconstitution of Ig class-switched and IgM⁺ memory B-cells has typically been attributed to
305 treatment-related damage to secondary lymphoid organs, which may hamper the formation of
306 germinal centers essential for somatic hypermutation and isotype switching⁴². Also for naive, Ig class-
307 switched, and IgM⁺ memory B-cells, we found that not only production rates but also cell loss rates
308 were increased 12 months post-autoHSCT, further supporting our conclusion that increased
309 lymphocyte production rates do not simply reflect a homeostatic response to low lymphocyte
310 numbers.

311 In brief, our findings show that despite the slow reconstitution of lymphocytes in autoHSCT
312 patients, lymphocyte production rates are increased. Since this increased production goes hand in
313 hand with increased cell loss, and does not normalize when cell numbers do, it is not simply due to
314 homeostatic mechanisms. Future studies should address whether the dynamics of lymphocytes after
315 autoHSCT normalize in the long run, what drives the increase in lymphocyte production and loss rates
316 during immune reconstitution, and to what extent immune reconstitution in the tissues occurs.

317 **Acknowledgments**

318 We thank the patients for their participation in this study, Jeroen F. van Velzen, Pien A.J. van der Burght
319 and Gerrit Spierenburg for assistance with cell sorting, Laura Ackermans for theoretical input, Lyanne
320 Derksen for critically reading the manuscript, Mr Benjamin Bartol and Ms Pei Mun Aui for technical
321 support, and the nurses from the Julius Center Trial Unit for taking care of study participants.

322 **Funding**

323 The research leading to these results has received funding from the European Union Seventh
324 Framework Programme (FP7/2007–2013) through the Marie-Curie Action “Quantitative T cell
325 Immunology” Initial Training Network, with reference number FP7-PEOPLE-2012-ITN 317040-QuanTI
326 and from the Landsteiner Foundation for Blood Transfusion Research (LSBR grant 0812).

327 **Authorship**

328 Contribution: MB-P, VvH, JD, JB and KT designed the experiments; MB-P and VvH performed the
329 experiments; LvdW and AJ selected and included the patients; MB-P, VH, JD, RdB, JB and KT analysed
330 and interpreted data; JD, RdB, and JB performed mathematical modelling; and all authors wrote and
331 approved the manuscript.

332 **Conflict-of-interest statements**

333 The authors declare no competing financial interests.

334


335 **References**

- 336 1. Lin Y, Kim J, Metter EJ, et al. Changes in blood lymphocyte numbers with age in vivo and their association
337 with the levels of cytokines/cytokine receptors. *Immun. Ageing*. 2016;13(1):24.
- 338 2. Wertheimer AM, Bennett MS, Park B, et al. Aging and Cytomegalovirus Infection Differentially and Jointly
339 Affect Distinct Circulating T Cell Subsets in Humans. *J. Immunol*. 2014;192(5):2143–2155.
- 340 3. Freitas AA, Rocha B. Population Biology of Lymphocytes: The Flight for Survival. *Annu. Rev. Immunol*.
341 2000;18(1):83–111.
- 342 4. Miller R a, Stutman O. T cell repopulation from functionally restricted splenic progenitors: 10,000-fold
343 expansion documented by using limiting dilution analyses. *J. Immunol*. 1984;133(6):2925–32.
- 344 5. Bell EB, Sparshott SM, Drayson MT, Ford WL. The stable and permanent expansion of functional T
345 lymphocytes in athymic nude rats after a single injection of mature T cells. *J. Immunol*. 1987;139(5):1379–
346 84.
- 347 6. Neujahr DC, Chen C, Huang X, et al. Accelerated Memory Cell Homeostasis during T Cell Depletion and
348 Approaches to Overcome It. *J. Immunol*. 2006;176(8):4632–4639.
- 349 7. Gaudin E, Rosado M, Agenes F, McLean A, Freitas AA. B-cell homeostasis, competition, resources, and
350 positive selection by self-antigens. *Immunol. Rev*. 2004;197:102–15.
- 351 8. Heining C, Spyridonidis A, Bernhardt E, et al. Lymphocyte reconstitution following allogeneic
352 hematopoietic stem cell transplantation: a retrospective study including 148 patients. *Bone Marrow*
353 *Transplant*. 2007;39(10):613–622.
- 354 9. Ringhoffer S, Rojewski M, Dohner H, Bunjes D, Ringhoffer M. T-cell reconstitution after allogeneic stem
355 cell transplantation: assessment by measurement of the sjTREC/ TREC ratio and thymic naive T cells.
356 *Haematologica*. 2013;98(10):1600–1608.
- 357 10. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. *Curr. Opin*.
358 *Hematol*. 2012;19(4):324–335.
- 359 11. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. *Semin*.

- 360 *Immunol.* 2007;19(5):318–330.
- 361 12. Jones JL, Thompson SAJ, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by
362 homeostatic T-cell proliferation. *Proc. Natl. Acad. Sci.* 2013;110(50):20200–20205.
- 363 13. Bouvy AP, Kho MML, Klepper M, et al. Kinetics of homeostatic proliferation and thymopoiesis after ratg
364 induction therapy in kidney transplant patients. *Transplantation.* 2013;96(10):904–913.
- 365 14. Hazenberg MD. T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell
366 transplantation are related to clinical events. *Blood.* 2002;99(9):3449–3453.
- 367 15. Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after
368 allogeneic stem cell transplantation contributes to chronic GVHD. *Blood.* 2017;127(5):646–658.
- 369 16. Westera L, van Hoven V, Drylewicz J, et al. Lymphocyte maintenance during healthy aging requires no
370 substantial alterations in cellular turnover. *Aging Cell.* 2015;14(2):219–227.
- 371 17. R Core Team (R Foundation for Statistical Computing). R: A Language and Environment for Statistical
372 Computing. 2018;
- 373 18. Van Gent R, Schadenberg AWL, Otto SA, et al. Long-term restoration of the human T-cell compartment
374 after thymectomy during infancy: A role for thymic regeneration? *Blood.* 2011;118(3):627–634.
- 375 19. Sauce D, Larsen M, Fastenackels S, et al. Lymphopenia-Driven Homeostatic Regulation of Naive T Cells in
376 Elderly and Thymectomized Young Adults. *J. Immunol.* 2012;189(12):5541–5548.
- 377 20. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. *Blood.*
378 2001;97(10):2983–90.
- 379 21. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1–mediated T-
380 cell depletion: implications for T-cell homeostasis. *Nat. Med.* 2001;7(1):73–79.
- 381 22. Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients:
382 relationship to clinical characteristics and lymphocyte count. *Bone Marrow Transplant.* 1999;23(8):783–
383 788.
- 384 23. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment
385 of HIV infection. *Nature.* 1998;396(6712):690–695.
- 386 24. Hazenberg MD, Otto SA, Cohen Stuart JW, et al. Increased cell division but not thymic dysfunction rapidly
387 affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. *Nat.*
388 *Med.* 2000;6(9):1036–42.
- 389 25. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, Dongen JJ. T cell receptor excision circles as
390 markers for recent thymic emigrants: Basic aspects, technical approach, and guidelines for
391 interpretation. *J. Mol. Med.* 2001;79(11):631–640.
- 392 26. Kohler S, Thiel A. Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. *Blood.*
393 2009;113(4):769–774.
- 394 27. van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. *Nat. Rev. Immunol.*
395 2018;18(June):
- 396 28. Hazenberg MD, Borghans JAM, de Boer RJ, Miedema F. Thymic output: a bad TREC record. *Nat. Immunol.*
397 2003;4(2):97–99.


- 398 29. Havenith SHC, Remmerswaal EBM, Bemelman FJ, et al. Rapid T cell repopulation after rabbit anti-
399 thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus. *Clin. Exp. Immunol.*
400 2012;169(3):292–301.
- 401 30. Bouvy AP, Klepper M, Betjes MGH, et al. Alemtuzumab as Antirejection Therapy. *Transplant. Direct.*
402 2016;2(6):e83.
- 403 31. Ponchel F, Cuthbert RJ, Goëb V. IL-7 and lymphopenia. *Clin. Chim. Acta.* 2011;412(1–2):7–16.
- 404 32. Brugnoli D, Airò P, Pennacchio M, et al. Immune reconstitution after bone marrow transplantation for
405 combined immunodeficiencies: down-modulation of Bcl-2 and high expression of CD95/Fas account for
406 increased susceptibility to spontaneous and activation-induced lymphocyte cell death. *Bone Marrow*
407 *Transplant.* 1999;23(5):451–457.
- 408 33. Lin MT, Tseng LH, Frangoul H, et al. Increased apoptosis of peripheral blood T cells following allogeneic
409 hematopoietic cell transplantation. *Blood.* 2000;95(12):3832–9.
- 410 34. Poulin J-F. Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic
411 hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. *Blood.*
412 2003;102(13):4600–4607.
- 413 35. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell
414 transplantation in humans. *Semin. Immunopathol.* 2008;30(4):425–37.
- 415 36. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to
416 differentiate directly into memory T cells. *J. Exp. Med.* 2000;192(4):549–56.
- 417 37. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during
418 homeostasis-driven proliferation. *J. Exp. Med.* 2000;192(4):557–64.
- 419 38. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after
420 autologous stem cell transplantation in multiple sclerosis patients. *J. Exp. Med.* 2005;201(5):805–816.
- 421 39. Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation
422 for multiple sclerosis. *J. Clin. Invest.* 2014;124(3):1168–72.
- 423 40. Dubinsky AN, Burt RK, Martin R, Muraro PA. T-cell clones persisting in the circulation after autologous
424 hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. *Bone Marrow Transplant.*
425 2010;45(2):325–331.
- 426 41. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after autologous transplantation for
427 lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. *Bone*
428 *Marrow Transplant.* 2003;32(2):177–186.
- 429 42. Avanzini MA, Locatelli F, Santos C Dos, et al. B lymphocyte reconstitution after hematopoietic stem cell
430 transplantation: functional immaturity and slow recovery of memory CD27+ B cells. *Exp. Hematol.*
431 2005;33(4):480–486.
- 432 43. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational Mini-Review Series on B cell subsets in
433 disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell
434 developmental pathways and lineage phenotypes. *Clin. Exp. Immunol.* 2012;167(1):15–25.

435 **Figure legends**




436

437 **Figure 1. Study protocol timeline and patient characteristics. (A)** Summary figure depicting the study
 438 time line of every patient. Patients are centred by start of $^2\text{H}_2\text{O}$ labelling. The left bar indicated the
 439 time between the autologous hematopoietic stem cell transplantation (autoHSCT) and the start of the
 440 labelling period, the grey area indicates the 6 weeks $^2\text{H}_2\text{O}$ labelling period, the right bar provides the
 441 follow up period and the vertical bars indicate the blood sampling time points. **(B)** Patient
 442 characteristics. Age=Age at start $^2\text{H}_2\text{O}$ labelling; M=Male; F=Female; Time post-HSCT=Reconstitution
 443 period at start $^2\text{H}_2\text{O}$ labelling; Medication usage=Medication during the study; HOVON 132 arm A
 444 (Idarubicin, Ara-C (Cytarabine), Daunorubicin); VCD (Bortezomib, Cyclophosphamide, Dexamethason);
 445 VMP (Bortezomib, Melphalan, Prednisone); VRD (Bortezomib, lenalidomide, dexamethasone); R-CHOP
 446 (Rituximab, Cyclophosphamide, Adriamycin, Vincristin, Prednisone); Ara-C (Cytarabine), TAD
 447 (Thalidomide, Adriamycin, Dexamethasone); CTD (Carfilzomib, Thalidomide, Dexamethasone); BEAM
 448 (Carmustine, Etoposide, Ara-C (Cytarabine), Melphalan). For absolute leukocytes, neutrophils,
 449 lymphocytes and monocytes numbers see Sup. Figure 6.




451 **Figure 2. T-cell reconstitution following autoHSCT. (A)** Absolute numbers (cells per milliliter) of total
452 CD3⁺ T-cells. **(B)** Absolute numbers (cells per milliliter) of CD4⁺ T-cells (CD3⁺CD4⁺), naive (CD27⁺CD45RO⁻
453) and memory (CD45RO⁺) CD4⁺ T-cells. **(C)** CD4:CD8 ratio. **(D)** Absolute numbers (cells per milliliter) of
454 CD8⁺ T-cells (CD3⁺CD8⁺), naive (CD27⁺CD45RO⁻) and memory (CD45RO⁺) CD8⁺ T-cells. **(A-D)** Graphs
455 show the absolute cell counts per milliliter or the CD4:CD8 ratio in autoHSCT patients (patients A to F)
456 over time from for the duration of the study, and the median and the corresponding IR for HCs (healthy
457 controls, grey area and whisker bars). **(E)** Bar graphs show the median percentage of naive
458 (CD27⁺CD45RO⁻), central memory (CM, CD27⁺CD45RO⁺), effector memory (EM, CD27⁺CD45RO⁺) and
459 effector (CD27⁻CD45RO⁻) CD4⁺ and CD8⁺ T-cells of autoHSCT patients (patients A to F) and HCs (naive
460 in blue, CM in orange, EM in green and effector in grey). For patient characteristics see Figure 1B, for
461 the T-cell subset distribution per patient over time see Sup. Figure 3.



462

463 **Figure 3. T-cell dynamics after autoHSCT. (A)** Deuterium enrichment in the DNA of naive and memory
 464 CD4⁺ and CD8⁺ T-cells in autoHSCT patients (A to F, color symbols), and healthy controls (HCs, grey
 465 symbols)¹⁶. Dotted lines correspond to the end of the labelling period (black for autoHSCT patients
 466 and grey for HCs). Label enrichment T was scaled between 0 and 100% by normalizing for the maximum
 467 enrichment in granulocytes (Sup. Figure 7). For individual fits see Sup. Figure 8. **(B)** Estimates of the
 468 per cell production rate of naive and memory CD4⁺ and CD8⁺ T-cells in autoHSCT patients and HCs¹⁶.
 469 Different symbols indicate different individuals, autoHSCT patients (A to F) in color and HCs in grey.
 470 Horizontal lines represent median values. P-values of significant differences between groups are
 471 shown.



472

473 **Figure 4. Contribution of peripheral proliferation and thymic output to T-cell production after**

474 **autoHSCT. (A)** Ki-67 expression was measured within naive and memory CD4⁺ (left panel) and CD8⁺

475 (right panel) T-cell in autoHSCT patients and HCs ¹⁶. **(B)** Average number of TRECs per naive CD4⁺ (left

476 panel) and CD8⁺ (right panel) T-cell in autoHSCT patients, cord blood (CB) and healthy controls (HCs)

477 ¹⁶. For *Patient A* and *Patient E*, TREC content was measured the first day of the study (t₀) as well as the

478 last study visit (t_{end}). For *Patient D*, TREC content was not successfully measured due to limited


479 material. **(C)** CD31 expression was measured within naive CD4⁺ T-cells in autoHSCT patients, cord blood

480 and HCs ¹⁶. For changes in CD31 expression and absolute numbers of CD31⁺ cells over time, see Sup.


481 Figure 4. Different symbols indicate different individuals, autoHSCT patients (A to F) in color, CB in dark

482 grey, and young (median age of 23 years) and old (median age of 68 years) HCs in light grey. Horizontal

483 lines represent median values. P-values of significant differences between groups are shown.




484
 485 **Figure 5. B-cell reconstitution following autoHSCT. (A)** Absolute numbers (cells per milliliter) of total
 486 CD19⁺ B-cells, naive (CD19⁺IgM⁺CD27⁻), Ig class-switched memory (CD19⁺IgM⁻CD27⁺) and IgM⁺ memory
 487 (CD19⁺IgM⁺CD27⁺) B-cells in peripheral blood over time. Graphs show the absolute cell counts per
 488 milliliter in autoHSCT patients (patients A to F) over the duration of the study, and the median and the
 489 corresponding IR (interquartile range) for HCs (healthy controls, grey area and whisker bars). **(B)** Bar
 490 graphs show the median percentage of naive, Ig class-switched memory and IgM⁺ memory B-cells
 491 within total CD19⁺ B-cells of autoHSCT patients (patients A to F) and HCs (naive in blue, natural effector
 492 in orange and memory in green). For the B-cell subset distribution per patient over time see Sup. Figure
 493 5. Note the different y-axes in panel A.



494

495 **Figure 6. B-cell dynamics after autoHSCT. (A)** Deuterium enrichment in the DNA of naive, Ig class-
 496 switched memory and IgM⁺ memory B-cells in autoHSCT patients (A to F, color symbols), and healthy
 497 controls (HCs, grey symbols)¹⁶. Dotted lines correspond to the end of the labelling period (black for

498 autoHSCT patients and grey for HCs). Label enrichment was scaled between 0 and 100% by normalizing
499 for the maximum enrichment in granulocytes for each patient (Sup. Figure 8). For individual fits see
500 Sup. Figure 9. **(B)** Estimates of the per cell production rates of naive, Ig class-switched memory and
501 IgM⁺ memory B-cells in autoHSCT patients and HCs ¹⁶. **(C)** Ki-67 expression was measured within naive,
502 Ig class-switched memory and IgM⁺ memory B-cells in autoHSCT patients and HCs ¹⁶. **(D)** Percentage of
503 naive B-cells containing a KREC and naive B-cell replication history for autoHSCT patients and HCs ¹⁶.
504 Different symbols indicate different individuals, autoHSCT patients (A to F) in color and HCs in grey.
505 Horizontal lines represent median values. P-values of significant differences between groups are
506 shown.



507
508 **Figure 7. Average T-cell and B-cell loss rates following autoHSCT. (A)** Estimates of the average loss
509 rates of naive and memory CD4⁺ and CD8⁺ T-cells and of **(B)** naive, Ig class-switched memory and IgM⁺
510 memory B-cells in autoHSCT patients (A to F, color symbols), and healthy controls (HC, grey symbols)
511 ¹⁶. Average loss rates were calculated using the estimated average turnover rates and the corrected
512 cell numbers (Sup. Figure 10 and 11) as described in supplementary material and methods. Horizontal
513 lines represent median values. P-values of significant differences between groups are shown.

514
515
516
517
518
519